|
Market Closed -
Oslo Bors
10:45:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 4.510 NOK | +10.00% |
|
+33.23% | +86.98% |
| 08-20 | Nykode Therapeutics Wins New US Patent for Neoantigen-based Cancer Vaccine | MT |
| 08-06 | Nykode Therapeutics Asa Announces Appointment of Jakob Helding Rasmussen as Chief Technology Officer | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 158M | - | - | - | - | - |
| 72.12B | |||||
| 65.85B | |||||
| 29.28B | - | ||||
| 27.47B | - | ||||
| 26.7B |
- Stock Market
- Stocks
- VACC Stock
- Charts Nykode Therapeutics
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
